lutetium-177 ST2210

Lutetium-177 (Lu-177) is a medical radioisotope utilized in targeted radionuclide therapy, primarily for treating certain cancers. It functions as a beta-emitter, releasing high-energy beta-minus particles that have a short path length in tissue. This characteristic enables highly localized radiation delivery to cancer cells, thereby minimizing damage to surrounding healthy tissues. Lu-177 is typically chelated to a targeting ligand, such as a peptide or small molecule, which is designed to specifically bind to receptors that are overexpressed on the surface of cancer cells. Upon binding, the Lu-177 delivers its cytotoxic radiation directly to the tumor cells, leading to DNA damage and subsequent cell death. This approach is often part of a theranostic strategy, combining therapy with potential diagnostic imaging capabilities due to the co-emission of low-energy gamma rays. Established applications of Lutetium-177 radiopharmaceuticals include the treatment of prostate cancer (by targeting Prostate-Specific Membrane Antigen, PSMA) and neuroendocrine tumors (by targeting somatostatin receptors).

Brand names

IART

Other names

lutetium lu 177 dota-biotinLu-177-ST2210Lu177-ST2210Lu 177-ST2210